Home » Diabetes, Cardiovascular Drug Developer PhaseBio Adds $15 Million
Diabetes, Cardiovascular Drug Developer PhaseBio Adds $15 Million
The Philadelphia-area biopharma company PhaseBio Pharmaceuticals has received the final $15 million of a $25 million investment to fund further testing of its lead drug, which focuses on hyperglycemia related to Type 2 diabetes.
MedCity News
MedCity News
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May